Shilpa Medicare gets 10 observations from USFDA for Jadcherla plant
New Delhi: Drug firm Shilpa Medicare said it has received 10 observations from the US health regulator for its formulation facilities at Jadcherla in Telangana.
The company "has received 483 observations from the United States Food and Drug Administration (USFDA) in relation to SEZ formulation facilities situated at Jadcherla, Telangana," Shilpa Medicare said in a filing to the BSE.
Total 10 observations were cited during the close-up meeting, it added.
While seven observations are regarding improvement in procedures and practices, three observations are related to the setting of analytical specifications, test procedures and method validation, Shilpa Medicare said.
As per the USFDA, observations are made in Form 483 when investigators feel that conditions or practices in the facility are such that products may become adulterated or render injuries to health.
The FDA Form 483 notifies the company's management of objectionable conditions.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd